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OBJECTIVES: Oral mucositis is a complication frequently associated with hematopoietic stem cell transplanta-
tion, decreasing a patient’s quality of life and increasing the occurrence of opportunistic infections. The
purpose of this study was to determine the incidence and severity of oral mucositis and to assess the correlation
of this disease with the oral health of an individual at the time of hematopoietic stem cell transplantation.
METHODS: Before transplantation, patients’ oral health and inflammatory conditions were determined using
the gingival index and the plaque index, which are based on gingival bleeding and the presence of dental
plaque, respectively. Additionally, the dental health status was determined using the decayed, missing, and
filled teeth index. The monitoring of oral mucositis was based on the World Health Organization grading
system and was performed for five periods: from Day 0 to D+5, from D+6 to D+10, from D+11 to D+15, from
D+16 to D+20, and from D+21 to D+30.
RESULTS: A total of 97 patients (56% male and 44% female) who underwent hematopoietic stem cell
transplantation at the Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo between
January 2008 and July 2009 were prospectively examined. The incidence of ulcerative mucositis was highest
from days +6 to +10 and from days +11 to +15 in the patients who underwent autologous and allogeneic
hematopoietic stem cell transplantation, respectively.
CONCLUSION: The data, including the dental plaque and periodontal status data, showed that these oral
health factors were predictive of the incidence and severity of oral mucositis in a cohort of patients with similar
conditioning regimens before hematopoietic stem cell transplantation.
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& INTRODUCTION
Oral mucositis (OM) is one of the most significant
complications of both autologous and allogeneic hemato-
poietic stem cell transplantation (HSCT) and is implicated in
extended hospitalization, prolonged narcotics use, and the
incidence of opportunistic infections (1,2). OM is the result
of damage to the epithelial and connective tissues by the
toxic effects of the HSCT conditioning regimen (3). The
clinical manifestations of OM include signs and symptoms
of inflammation, varying from mild erythema, edema, and
soreness to severe pain and ulceration that require analgesic
medication (4). Severe OM interferes with daily activities,
such as speaking, eating, and swallowing, resulting in
dehydration, malnutrition, and opportunistic infections,
with a negative impact on the quality of life (5,6) and
possibly leading to lower overall survival after HSCT (7).
Comprehensive oral care prior to HSCT is related to
briefer OM (8,9). OM negatively affects the transplantation
outcome by facilitating opportunistic infections and sepsis,
so clinical approaches to reducing OM incidence or severity
may increase patient survival and quality of life. The
purpose of this study was to determine the incidence and
severity of OM and to assess the correlation of this disease
with the oral health of an individual at the time of HSCT.
& PATIENTS AND METHODS
Ninety-seven patients with hematological or solid tumors
who underwent HSCT (62 autologous and 35 allogeneic)
were enrolled in this prospective study. Patients were all
examined in two or more occasions (intraexaminer error) by
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the same dentist with expertise and training in OM clinical
manifestations and diagnosis. The conditioning regimen
comprised high-dose chemotherapy without radiation for
all of the participants. Graft-versus-host disease (GVHD)
prophylaxis in the allogeneic HSCT patients consisted of
cyclosporin A plus a short course of methotrexate (MTX) (on
days +1, +3, +6, and +11). Supportive care consisted of
broad-spectrum antibiotics in addition to antifungal and
antiviral prophylaxis, which began at the start of the
conditioning regimen. The broad-spectrum antibiotics were
changed when the fever was positive. Furthermore, pre-
emptive ganciclovir therapy was prescribed when cytome-
galovirus (CMV) infection was evident.
The patients were well instructed by the same oral care
professional about dental cleaning and oral hygiene. The
specific directives were to clean the oral cavity daily and to
rinse with chamomile tea. Oral health was assessed using a
transversal evaluation immediately before transplantation
and was determined using the gingival index (GI) and the
plaque index (PI), which are based on gingival bleeding and
the presence of dental plaque, respectively (10,11). The
dental health status was determined by the DMFT index,
which numerically expresses the prevalence of caries in an
individual and is obtained by calculating the number of
decayed (D), missing (M), and filled (F) teeth. OM
monitoring started on D+1 and continued until D+30 post-
transplantation. OM was graded based on the World Health
Organization (WHO) grading system (grade 0: no OM;
grade 1: pain and erythema; grade 2: ulcerations and can eat
solids; grade 3: large ulcers and no solid intake but liquid
diet possible; and grade 4: large ulcerations and solid/liquid
intake not possible). All of the patients were evaluated daily
by the same dentist, and the data were recorded for five
periods: from Day 0 to D+5, from D+6 to D+10, from D+11 to
D+15, from D+16 to D+20, and from D+21 to D+30. These
periods were selected according to the biology of the bone
marrow nadir until complete recovery.
Endpoint
The primary endpoint was the incidence of OM at any
grade and of any severity in HSCT patients, according to the
patients’ oral health at the time of transplantation.
Statistical analysis
A linear regression was performed to determine the
relationship between oral health (using the plaque, gingival,
and DMFT indexes) and the incidence of OM. Additionally,
analysis of variancewas employed to establish howoral health
indexes influence OM. The differences in categorical variables
between the groups were evaluated using Fisher’s exact test.
Ethics
All of the patients signed an informed consent form that
was approved by the Institutional Research and Medical
Ethics Committee.
& RESULTS
Ninety-seven patients (54 males and 43 females) were
enrolled in this prospective study. The median age was 41
years old (range: 18 to 65 years). The complete demographic
data for both groups are presented in Table 1. Among the
patients, OM grade I on the WHO scale was experienced by
47 (48.5%), grade II by 25 (25.8%), grade III by 8 (8.2%), and
grade IV by 8 (8.2%). Nine (9.3%) patients did not
experience any OM. Ulcerative mucositis scores of grades
III and IV, according to the WHO assessment scale,
revealed a higher incidence from days +6 to +10 in
autologous HSCT patients and from days +11 to +15 in
allogeneic HSCT patients (Figure 1). An overall evaluation
showed a higher incidence of OM, comprising the more
severe grades III and IV, with impaired food intake, in
allogeneic HSCT patients than in autologous HSCT patients
(p,0.001).
Oral health index evaluation
According to the PI and GI evaluations, the medians of
both indexes were 0.42, and the ranges were from 0.0 to 1.67
for the PI and from 0.0 to 1.90 for the GI. Moreover, the
dental DMFT index ranged from 0.0 to 32, with a median of
15.5. The incidence of OM was assessed according to each of
the three oral indexes (PI, GI, and DMFT), and the results
showed that both the GI (p=0.04) and the PI (p= 0.01)
positively affected the incidence of OM. Additionally, when
the autologous and allogeneic HSCT groups of patients
were analyzed separately, the GI and PI were correlated
with a higher incidence of OM in each group. In contrast,
the dental status measured by the DMFT index did not
influence the incidence of OM in either group.
OM and conditioning regimen
Regardless of the type of high-dose chemotherapy used as
a conditioning regimen for HSCT, no difference was noted
when comparing high-dose melphalan (Bu/Mel and BEAM)
with the other regimen (Bu/Cy and Flu/Mel) (p= 0.4104). A
conditioning regimen for allogeneic HSCT that included
MTX showed a higher incidence of OM compared with a
regimen for autologous HSCT that lacked MTX (p= 0.0004).
Table 1 - Patient characteristics.
Autologous Allogeneic (MTX)
Gender (F/M) 31/31 12/23
Median Age (range) 42.5 (19-65) 40 (18-60)
Underlying Diseases
SAA 0 5
HD 12 0
AML 12 10
CML 0 4
NHL 10 3
MM 25 0
MDS 0 9
Other 0 1
ALL 1 3
Testicular Carcinoma 2 0
Conditioning Regimen
BEAM 17 0
Flu/Mel 0 1
Bu/Cy 0 5
Bu/Mel 45 29
MTX use - 35
F: female; M: male; MTX: methotrexate; SAA: severe aplastic anemia; HD:
Hodgkin disease; AML: acute myelogenous leukemia; CML: chronic
myelogenous leukemia; NHL: non-Hodgkin lymphoma; MM: multiple
myeloma; MDS: myelodysplastic syndrome; ALL: acute lymphocytic
leukemia; BEAM: conditioning regimen comprising becenum, etoposide,
cytarabine, and melphalan; Flu: fludarabine; Mel: melphalan; Bu:
busulfan; Cy: cyclophosphamide.
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& DISCUSSION
HSCT can lead to acute complications in the oral mucosa
and salivary glands (1,12). Recently, we showed that
comprehensive oral care is directly related to the incidence
of OM (9). In this study, our results showed that dental
plaque, a known causative factor in oral inflammation, was
a determinant of the incidence of OM.
OM is a major debilitating complication of stem cell
transplantation that causes distressing symptoms in patients
and has economic and clinical implications (1). Although OM
is a widely studied condition, the current prospective study
identifies oral health at the time of transplantation to be an
important predictive factor for OM incidence. Ruescher and
colleagues (2) reported an increase in alpha hemolytic
bacteremia in OM after autologous stem cell transplantation.
The researchers also considered the economic and clinical
importance of OM. An increase in cost and longer hospita-
lization were also demonstrated to be associated with OM by
Sonis et al. (1). Dental plaque and periodontal disease are two
factors contributing to bacteremia after transplantation,
thereby increasing hospitalization. Dentists must address
these issues to reduce complications after HSCT.
It is well established that OM incidence is higher in
allogeneic, rather than autologous, HSCT, possibly as a
consequence of MTX administration in allogeneic HSCT.
Clinicians should provide more attention to these allogeneic
HSCT patients due to the patients’ higher incidence of OM
(13,14). Ohbayashi et al. (13) reported an 80.5% incidence of
OM in a group using MTX, compared with 19.5% in a group
that did not use this drug (13). In another study, Wardley
et al. (15) reported the highest OM incidence for melphalan
Figure 1 - Global incidence of OM in the patients during the assessment periods (WHO grading scale).
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200 (3.6), followed by busulfan (2.6), cyclophosphamide/
TBI (2.3), and cyclophosphamide-carmustine and CVB (1.4).
In the current study, the patients underwent high-dose
chemotherapy without total body irradiation as a prepara-
tive regimen. The objective was to analyze similar con-
ditioning regimens, with most patients using high-dose
melphalan followed by BEAM. Our results show that there
was no association between the preparative regimens and
that the incidence of OM was similar between the groups
(p= 0.4104).
However, a higher OM incidence was noted when
comparing the regimens that included MTX. In addition,
the allogeneic HSCT group exhibited a longer healing time
than the autologous HSCT group (p,0.001). The data
presented here show that OM is not only caused by the
conditioning regimen but also by other factors, such as oral
health status. OM in the patients enrolled in this study was
evaluated using the WHO grading scale.
Melkos and colleagues (16) reported that patients with no
dental care before HSCT showed a higher incidence of
complications, indicating the importance of a dental
evaluation and appropriate intervention before HSCT. In a
complementary study, the incidence of OM was compared
between patients who did and did not receive oral care
before HSCT. The results showed no differences in OM
incidence, although the healing time was reduced in the
patients who received oral care (9). In the present study, the
PI and GI were positively correlated with OM incidence.
This finding is consistent with the assumption that oral care
prior to HSCT can decrease OM severity and incidence by
reducing dental plaque and gingival inflammation.
Recently, our group reported that reducing dental plaque
and gingival inflammation by oral care was positively
correlated with OM (9), corroborating the idea that oral
inflammation is predictive of OM incidence and healing
time.
Cancer treatment is becoming increasingly more effective
but is associated with both short-term and long-term side
effects. Oral side effects continue to cause complications
despite the variety of agents used to prevent these effects.
One of the side effects is oral mucositis, a very debilitating
condition. Thus, protocols for preventing and treating OM
in patients with a reduced salivary flow and/or dental
caries are necessary. These patients require prophylactic
care to avoid life-threatening systemic infections that begin
in the mouth (17). We agree with other authors that good
oral health directly influences patients’ quality of life (9), so
a standardized oral care protocol with regular and
systematic oral hygiene, comprising brushing and flossing,
must be part of the multidisciplinary approach to treating
HSCT patients (18).
In conclusion, the data, including the dental plaque and
periodontal status data, showed that these oral health
factors were predictive of OM incidence and severity in a
cohort of patients with similar conditioning regimens before
HSCT.
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